The Latin America, Middle East and Africa Pruritus Therapeutics Market would witness market growth of 6.1% CAGR during the forecast period (2023-2030).
The potential for the creation of innovative therapeutics for pruritus is significant. Exploration in targeted medicines, biologics, and gene therapies provides promise for more specialized and effective treatment alternatives. Because of the increased prevalence of illnesses associated with pruritus, the expanding healthcare infrastructure, and the rising cost of healthcare, the market offers considerable potential in emerging markets.
The skin condition known as urticaria, also called hives, is highly prevalent and establishes millimeter- to centimeter-sized red, itchy lumps on the skin. They can appear in any area of the body. Most allergists recommend antihistamines like cetirizine, fexofenadine, and loratadine to treat urticaria symptoms. The monitoring and managing pruritus can also be improved by integrating digital health technology, including telemedicine, smartphone apps, and wearables. These technologies offer possibilities for real-time data gathering for research goals, customized therapies, and remote patient monitoring. Topical medications such as corticosteroids, antihistamines, and calcineurin inhibitors are usually recommended for mild to severe pruritus. These drugs serve by calming the skin's inflammation, suppressing itch sensations, and hydrating the skin.
The varying tropical, temperate, and frigid temperatures in Latin American nations may directly affect the prevalence of A.D. According to a Brazilian study, 23% of adult A.D. patients and 39% of those with severe depression also had moderate-to-severe depression. According to the "Healthcare Resource Utilization and Direct Cost of Patients with Atopic Dermatitis in Dubai, United Arab Emirates: A Retrospective Cohort Study," AD is a common skin condition in Dubai (UAE) with a 4-5% prevalence rate. Most patients (about 90%) receive specialized care for their situation. According to estimates, the region's high AD prevalence will help increase the regional market.
The Brazil market dominated the LAMEA Pruritus Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $211.6 million by 2030. The Argentina market is estimated to grow at a CAGR of 6.7% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 5.8% during (2023 - 2030).
Based on Disease Type, the market is segmented into Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria and Others. Based on Product, the market is segmented into Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Pruritus Therapeutics Market is Projected to reach USD 11.2 Billion by 2030, at a CAGR of 4.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bristol Myers Squibb Company, Novartis AG, Pfizer, Inc., Sanofi S.A., Astellas Pharma, Inc., Cara Therapeutics, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceuticals Industries Ltd., Amgen, Inc., and AbbVie, Inc.
By Disease Type
By Product
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
